Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). Th...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Cappelli, Laura C. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values - Hedayati, Sara ELSEVIER, 2016transfer abstract, Philadelphia, Pa |
|---|---|
| Übergeordnetes Werk: |
volume:48 ; year:2018 ; number:3 ; pages:553-557 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.semarthrit.2018.02.011 |
|---|
| Katalog-ID: |
ELV045234345 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045234345 | ||
| 003 | DE-627 | ||
| 005 | 20230624114156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190205s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semarthrit.2018.02.011 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000653.pica |
| 035 | |a (DE-627)ELV045234345 | ||
| 035 | |a (ELSEVIER)S0049-0172(18)30042-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 570 |a 610 |q VZ |
| 084 | |a 58.30 |2 bkl | ||
| 084 | |a 50.22 |2 bkl | ||
| 084 | |a 44.09 |2 bkl | ||
| 100 | 1 | |a Cappelli, Laura C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| 264 | 1 | |c 2018 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. | ||
| 650 | 7 | |a Immune checkpoint inhibitor |2 Elsevier | |
| 650 | 7 | |a Inflammatory arthritis |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 650 | 7 | |a Cancer |2 Elsevier | |
| 700 | 1 | |a Brahmer, Julie R. |4 oth | |
| 700 | 1 | |a Forde, Patrick M. |4 oth | |
| 700 | 1 | |a Le, Dung T. |4 oth | |
| 700 | 1 | |a Lipson, Evan J. |4 oth | |
| 700 | 1 | |a Naidoo, Jarushka |4 oth | |
| 700 | 1 | |a Zheng, Lei |4 oth | |
| 700 | 1 | |a Bingham, Clifton O. |4 oth | |
| 700 | 1 | |a Shah, Ami A. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Saunders |a Hedayati, Sara ELSEVIER |t Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |d 2016transfer abstract |g Philadelphia, Pa |w (DE-627)ELV013670425 |
| 773 | 1 | 8 | |g volume:48 |g year:2018 |g number:3 |g pages:553-557 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.semarthrit.2018.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_181 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 936 | b | k | |a 58.30 |j Biotechnologie |q VZ |
| 936 | b | k | |a 50.22 |j Sensorik |q VZ |
| 936 | b | k | |a 44.09 |j Medizintechnik |q VZ |
| 951 | |a AR | ||
| 952 | |d 48 |j 2018 |e 3 |h 553-557 |g 5 | ||
| author_variant |
l c c lc lcc |
|---|---|
| matchkey_str |
cappellilauracbrahmerjulierfordepatrickm:2018----:lnclrsnainfmuehcpitniioidcdnlmaoyrhiidf |
| hierarchy_sort_str |
2018 |
| bklnumber |
58.30 50.22 44.09 |
| publishDate |
2018 |
| allfields |
10.1016/j.semarthrit.2018.02.011 doi GBV00000000000653.pica (DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 DE-627 ger DE-627 rakwb eng 540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Cappelli, Laura C. verfasserin aut Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen 2018 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier Brahmer, Julie R. oth Forde, Patrick M. oth Le, Dung T. oth Lipson, Evan J. oth Naidoo, Jarushka oth Zheng, Lei oth Bingham, Clifton O. oth Shah, Ami A. oth Enthalten in Saunders Hedayati, Sara ELSEVIER Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values 2016transfer abstract Philadelphia, Pa (DE-627)ELV013670425 volume:48 year:2018 number:3 pages:553-557 extent:5 https://doi.org/10.1016/j.semarthrit.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 58.30 Biotechnologie VZ 50.22 Sensorik VZ 44.09 Medizintechnik VZ AR 48 2018 3 553-557 5 |
| spelling |
10.1016/j.semarthrit.2018.02.011 doi GBV00000000000653.pica (DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 DE-627 ger DE-627 rakwb eng 540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Cappelli, Laura C. verfasserin aut Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen 2018 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier Brahmer, Julie R. oth Forde, Patrick M. oth Le, Dung T. oth Lipson, Evan J. oth Naidoo, Jarushka oth Zheng, Lei oth Bingham, Clifton O. oth Shah, Ami A. oth Enthalten in Saunders Hedayati, Sara ELSEVIER Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values 2016transfer abstract Philadelphia, Pa (DE-627)ELV013670425 volume:48 year:2018 number:3 pages:553-557 extent:5 https://doi.org/10.1016/j.semarthrit.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 58.30 Biotechnologie VZ 50.22 Sensorik VZ 44.09 Medizintechnik VZ AR 48 2018 3 553-557 5 |
| allfields_unstemmed |
10.1016/j.semarthrit.2018.02.011 doi GBV00000000000653.pica (DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 DE-627 ger DE-627 rakwb eng 540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Cappelli, Laura C. verfasserin aut Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen 2018 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier Brahmer, Julie R. oth Forde, Patrick M. oth Le, Dung T. oth Lipson, Evan J. oth Naidoo, Jarushka oth Zheng, Lei oth Bingham, Clifton O. oth Shah, Ami A. oth Enthalten in Saunders Hedayati, Sara ELSEVIER Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values 2016transfer abstract Philadelphia, Pa (DE-627)ELV013670425 volume:48 year:2018 number:3 pages:553-557 extent:5 https://doi.org/10.1016/j.semarthrit.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 58.30 Biotechnologie VZ 50.22 Sensorik VZ 44.09 Medizintechnik VZ AR 48 2018 3 553-557 5 |
| allfieldsGer |
10.1016/j.semarthrit.2018.02.011 doi GBV00000000000653.pica (DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 DE-627 ger DE-627 rakwb eng 540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Cappelli, Laura C. verfasserin aut Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen 2018 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier Brahmer, Julie R. oth Forde, Patrick M. oth Le, Dung T. oth Lipson, Evan J. oth Naidoo, Jarushka oth Zheng, Lei oth Bingham, Clifton O. oth Shah, Ami A. oth Enthalten in Saunders Hedayati, Sara ELSEVIER Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values 2016transfer abstract Philadelphia, Pa (DE-627)ELV013670425 volume:48 year:2018 number:3 pages:553-557 extent:5 https://doi.org/10.1016/j.semarthrit.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 58.30 Biotechnologie VZ 50.22 Sensorik VZ 44.09 Medizintechnik VZ AR 48 2018 3 553-557 5 |
| allfieldsSound |
10.1016/j.semarthrit.2018.02.011 doi GBV00000000000653.pica (DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 DE-627 ger DE-627 rakwb eng 540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Cappelli, Laura C. verfasserin aut Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen 2018 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier Brahmer, Julie R. oth Forde, Patrick M. oth Le, Dung T. oth Lipson, Evan J. oth Naidoo, Jarushka oth Zheng, Lei oth Bingham, Clifton O. oth Shah, Ami A. oth Enthalten in Saunders Hedayati, Sara ELSEVIER Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values 2016transfer abstract Philadelphia, Pa (DE-627)ELV013670425 volume:48 year:2018 number:3 pages:553-557 extent:5 https://doi.org/10.1016/j.semarthrit.2018.02.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 58.30 Biotechnologie VZ 50.22 Sensorik VZ 44.09 Medizintechnik VZ AR 48 2018 3 553-557 5 |
| language |
English |
| source |
Enthalten in Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values Philadelphia, Pa volume:48 year:2018 number:3 pages:553-557 extent:5 |
| sourceStr |
Enthalten in Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values Philadelphia, Pa volume:48 year:2018 number:3 pages:553-557 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Biotechnologie Sensorik Medizintechnik |
| institution |
findex.gbv.de |
| topic_facet |
Immune checkpoint inhibitor Inflammatory arthritis Immunotherapy Cancer |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |
| authorswithroles_txt_mv |
Cappelli, Laura C. @@aut@@ Brahmer, Julie R. @@oth@@ Forde, Patrick M. @@oth@@ Le, Dung T. @@oth@@ Lipson, Evan J. @@oth@@ Naidoo, Jarushka @@oth@@ Zheng, Lei @@oth@@ Bingham, Clifton O. @@oth@@ Shah, Ami A. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013670425 |
| dewey-sort |
3540 |
| id |
ELV045234345 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045234345</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624114156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.semarthrit.2018.02.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000653.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045234345</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0049-0172(18)30042-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.22</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.09</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cappelli, Laura C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune checkpoint inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammatory arthritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brahmer, Julie R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Forde, Patrick M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le, Dung T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lipson, Evan J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naidoo, Jarushka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bingham, Clifton O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Ami A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Saunders</subfield><subfield code="a">Hedayati, Sara ELSEVIER</subfield><subfield code="t">Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values</subfield><subfield code="d">2016transfer abstract</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV013670425</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:553-557</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.semarthrit.2018.02.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.22</subfield><subfield code="j">Sensorik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.09</subfield><subfield code="j">Medizintechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">553-557</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| author |
Cappelli, Laura C. |
| spellingShingle |
Cappelli, Laura C. ddc 540 ddc 570 bkl 58.30 bkl 50.22 bkl 44.09 Elsevier Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| authorStr |
Cappelli, Laura C. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013670425 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 570 - Life sciences; biology 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer Elsevier |
| topic |
ddc 540 ddc 570 bkl 58.30 bkl 50.22 bkl 44.09 Elsevier Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer |
| topic_unstemmed |
ddc 540 ddc 570 bkl 58.30 bkl 50.22 bkl 44.09 Elsevier Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer |
| topic_browse |
ddc 540 ddc 570 bkl 58.30 bkl 50.22 bkl 44.09 Elsevier Immune checkpoint inhibitor Elsevier Inflammatory arthritis Elsevier Immunotherapy Elsevier Cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j r b jr jrb p m f pm pmf d t l dt dtl e j l ej ejl j n jn l z lz c o b co cob a a s aa aas |
| hierarchy_parent_title |
Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |
| hierarchy_parent_id |
ELV013670425 |
| dewey-tens |
540 - Chemistry 570 - Life sciences; biology 610 - Medicine & health |
| hierarchy_top_title |
Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013670425 |
| title |
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| ctrlnum |
(DE-627)ELV045234345 (ELSEVIER)S0049-0172(18)30042-8 |
| title_full |
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| author_sort |
Cappelli, Laura C. |
| journal |
Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |
| journalStr |
Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
553 |
| author_browse |
Cappelli, Laura C. |
| container_volume |
48 |
| physical |
5 |
| class |
540 VZ 570 VZ 570 610 VZ 58.30 bkl 50.22 bkl 44.09 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Cappelli, Laura C. |
| doi_str_mv |
10.1016/j.semarthrit.2018.02.011 |
| dewey-full |
540 570 610 |
| title_sort |
clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| title_auth |
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| abstract |
Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. |
| abstractGer |
Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. |
| abstract_unstemmed |
Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_22 GBV_ILN_24 GBV_ILN_40 GBV_ILN_65 GBV_ILN_181 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2011 |
| container_issue |
3 |
| title_short |
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen |
| url |
https://doi.org/10.1016/j.semarthrit.2018.02.011 |
| remote_bool |
true |
| author2 |
Brahmer, Julie R. Forde, Patrick M. Le, Dung T. Lipson, Evan J. Naidoo, Jarushka Zheng, Lei Bingham, Clifton O. Shah, Ami A. |
| author2Str |
Brahmer, Julie R. Forde, Patrick M. Le, Dung T. Lipson, Evan J. Naidoo, Jarushka Zheng, Lei Bingham, Clifton O. Shah, Ami A. |
| ppnlink |
ELV013670425 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.semarthrit.2018.02.011 |
| up_date |
2024-07-06T16:58:28.078Z |
| _version_ |
1803849677491142656 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045234345</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624114156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.semarthrit.2018.02.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000653.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045234345</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0049-0172(18)30042-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.30</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.22</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.09</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cappelli, Laura C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy, increasingly utilized to treat malignancies. Inflammatory arthritis (IA) is a potential consequence of ICI use, but there is limited information to guide evaluation and management of this immune-related adverse event (irAE). This study aimed to characterize clinical phenotypes, IA treatment and response in the largest cohort of patients with ICI-induced IA reported to date.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immune checkpoint inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inflammatory arthritis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brahmer, Julie R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Forde, Patrick M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le, Dung T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lipson, Evan J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Naidoo, Jarushka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zheng, Lei</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bingham, Clifton O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Ami A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Saunders</subfield><subfield code="a">Hedayati, Sara ELSEVIER</subfield><subfield code="t">Physical properties of pregelatinized and granular cold water swelling maize starches at different pH values</subfield><subfield code="d">2016transfer abstract</subfield><subfield code="g">Philadelphia, Pa</subfield><subfield code="w">(DE-627)ELV013670425</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:553-557</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.semarthrit.2018.02.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.30</subfield><subfield code="j">Biotechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.22</subfield><subfield code="j">Sensorik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.09</subfield><subfield code="j">Medizintechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">553-557</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.400199 |